StockData
Maze Therapeutics, Inc. logo

Maze Therapeutics, Inc. (MAZE) stock

MAZENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30
$32.87−1.03 (-3.04%)

Close on Nov 17, 2026Market cap $1.83BP/E –Yield –

Maze Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Maze Therapeutics's pe ratio was 12.4× on Jul 31, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 202512.4×–

More Maze Therapeutics figures

See a number that looks wrong?